Biotechnology - Teva Pharmaceutical Industries


Popular Filters

Israel's Clal Biotech in talks to sell Andromeda unit


In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February…

Andromeda BiotechBiotechnologyClal BiotechnologyDiabetesDiaPep277Mergers & AcquisitionsTeva Pharmaceutical Industries

Gilead and Teva settle Viread patent litigation


US biotech firm Gilead Sciences (Nasdaq: GILD), a global leader in the HIV/AIDS drug market, has reached…

Anti-viralsBiotechnologyGenericsGilead SciencesNorth AmericaPatentsTeva Pharmaceutical IndustriesViread

Teva pulls out of CureTech deal; AC Immune drops CI-91


Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) says that it has terminated its collaboration…

AC ImmuneBiotechnologyCT-011CureTechLicensingNeurologicalOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Galena Biopharma leaps on deal with Teva for NeuVax in Israel


Shares of US biotech firm Galena Biopharma (Nasdaq: GALE) leapt 13.7% to $2.32 in pre-market trading…

BiotechnologyGalena BioPharmaLicensingnelipepimut-SNeuVaxOncologyRest of the WorldTeva Pharmaceutical IndustriesVaccines

Novogen to acquire Triaxial Pharma for $1.8 million; EU approves Teva/P&G deal


Biotechnology firm Novogen (ASX: NRT) yesterday announced that it has signed a term sheet in relation…

BiotechnologyMergers & AcquisitionsNovogenPharmaceuticalProcter & GambleRegulationTeva Pharmaceutical IndustriesTriaxial Pharmaceuticals

M&A briefs: GlaxoSmithKline/Response Genetics; Bayer/Teva unit


USA-based Response Genetics (Nasdaq: RGDX) last week entered into a purchase agreement with UK pharma…

BayerBiotechnologyFinancialGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalResponse GeneticsTeva Pharmaceutical Industries

FDA approves pediatric Afinitor from Novartis and Teva's tbo-filgrastim


The US Food and Drug Administration yesterday approved Swiss drug major Novartis' (NOVN: VX) Afinitor…

AfinitorBiotechnologyGenericsNorth AmericaNovartisOncologyPharmaceuticalRegulationSicor Biotechtbo-filgrastimTeva Pharmaceutical Industries

Teva and OncoGenex update on prostate cancer drug development; loss widens at latter


Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) and US/Canadian partner OncoGenex Pharmaceuticals…

BiotechnologycustirsenFinancialLicensingOncoGenexPharmaceuticalResearchTeva Pharmaceutical Industries

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint


Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial…

AndromedaBiotechnologyClal BiotechnologyDiabetesDiaPep277ResearchTeva Pharmaceutical Industries

As global MS pipelines revealed, Gilenya maintains strongest appeal, says Nomura analyst


Following the September 2010 US launch, Swiss drug major Novartis’ (NOVN: VX) first-in-class, once-daily…

AubagioBiogen IdecBiotechnologyGilenyalaquinimodLemtradaMarkets & MarketingNeurologicalNovartisocrelizumabPharmaceuticalResearchRocheSanofiTeva Pharmaceutical Industries

Merck returns safinamide rights to Newron; ImmuPharma regains Lupuzor from Cephalon


As part of the ongoing review and re-prioritization of its R&D pipeline, biotech firm Merck Serono, a…

BiotechnologyCephalonLicensingLupuzorMerck KGaAMerck SeronoNeurologicalNewron PharmaPharmaceuticalRare diseasessafinamideTeva Pharmaceutical Industries

Back to top